Currently, a standardized definition and classification system for drug-nutrient interactions does not exist. This may explain the disparity in the perception, recognition, and management of drug-nutrient interactions among clinicians and researchers. The purpose of this article is to redefine and systematically classify drug-nutrient interactions according to the most recent understanding in drug and nutrient metabolism and drug-drug interactions. Drug-nutrient interactions can be broadly classified into four types based on their mechanisms. This definition and classification system should facilitate patient management, clinical and didactic training for practitioners, and future research direction in this area.
2. Bauer LA: Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology32(5):570–572, 1982
3.
3. Ozuna J, Friel P: Effect of enteral tube feeding on serum phenytoin levels. J Neurosurg Nurs16(6):289–291, 1984
4.
4. A.S.P.E.N. Board of Directors. Standard of practice for nutrition support pharmacists. Nutr Clin Pract14(5):275–281, 1999
5.
5. Mueller BA, Bricrton DG, Abel SR, et al: Effect of enteral feeding with ensure on oral bioavailabilities of of loxacin and ciprofloxacin. Antimicrob Agents Chemother38(9):2101–2105, 1994
6.
6. Mimoz O, Binter V, Jacolot A, et al: Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med24(10):1047–1051, 1998
7.
7. Pirsch JD, Armbrust MJ, Knechtle SJ, et al: Obesity as a risk factor following renal transplantation. Transplantation59:631–647, 1995
8.
8. Shane E, Rivas M, McMahon DJ, et al: Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab82(5): 1497–1506, 1997
9.
9. 1997 Comprehensive Accreditation Manual for Hospitals. Chicago. Joint Commission on Accreditation of Healthcare Organizations, 1997
10.
10. Garg SK, Kumar N, Bhargava VK, et al: Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther64:286–288, 1998
11.
11. Lewis DP, Van Dyke DC, Willhite LA, et al: Phenytoin-folic acid interaction. Ann Pharmacother29:726–735, 1995
12.
12. Chang T, Benet LA, Hebert MF: The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther59:297–303, 1996
13.
13. Ducharme MP, Warbasse LH, Edwards DJ: Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther57:485–491, 1995
14.
14. Fuhr U: Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf18(4):251–272, 1998
15.
15. Melia AT, Koss-Twardy SG, Zhi J: The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol36(7):647–653, 1996
16.
16. Neuvonen PJ, Kivisto KT, Lehto P: Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther50(5 Pt l):498–502, 1991
17.
17. Booth SL, Centurelli MA: Vitamin K: A practical guide to the dietary management of patients on warfarin. Nutr Rev57(9 Pt l):288–296, 1999
19. Nielsen HK, Brixen K, Kassem M, et al: Acute effect of 1,25-dihydroxyvitamin D3, prednisone, and 1,25-dihydroxyvitamin D3 plus prednisone on serum osteocalcin in normal individuals. J Bone Miner Res6(5):435–441, 1991
20.
20. Triggs WJ, Bohan TP, Lin SN, et al: Valproate-induced coma with ketosis and carnitine insufficiency. Arch Neurol47:1131–1133, 1990
21.
21. Ohtani Y, Endo F, Matsuda I: Carnitine deficiency with hyperammonemia associated with valproic acid therapy. J Pediatr101:782–785, 1982
22.
22. Triggs WJ, Gilmore RL, Millington DS, et al: Valproate-associ-ated carnitine deficiency and malignant cerebral edema in the absence of hepatic failure. Int J Clin Pharmacol Ther35(9):353–356, 1997
23.
23. Bennett WM: Drug interactions and consequences of sodium restriction. Am J Clin Nutr65(2 SuppI):678S–681, 1997
